2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosis
2020
Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration
Hung P, Hsu SH, Wang SY. Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration. Value In Health 2020, 23: 697-704. PMID: 32540226, DOI: 10.1016/j.jval.2020.01.021.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseCongestive heart failureEOL expendituresHospice staysEnd Results-Medicare dataLonger hospice staysObstructive pulmonary diseaseMonths of lifeDays of lifeDistinct disease trajectoriesPatient disease groupsCancer decedentsDifferential associationsHeart failureAggressive endPulmonary diseaseHospice lengthMedical covariatesCancer patientsHospice useDisease groupClinical conditionsLife careDisease trajectoriesPatients